

Anxiety Disorders

DSM-IV-TR Diagnostic Code: 300.02 Generalized Anxiety Disorder
 300.0 Anxiety Disorder NOS
 300.01 Panic Disorder Without Agoraphobia
 300.21 Panic Disorder With Agoraphobia
 300.23 Social Phobia (Social Anxiety Disorder)
 300.29 Specific Phobia

Diagnostic Guidelines

1. Establish diagnostic accuracy as defined in DSM-IV-TR.
2. Assess for co-morbid depression.
3. Assess for family history of mental illness.
4. Consider cultural factors, such as religious or spiritual beliefs.
5. Rule out the effects of intoxication and withdrawal, of prescription and/or street drugs and ETOH.
6. Rule out medical conditions such as: thyroid dysfunction, mitral valve prolapse, cardiac arrhythmias and hypoglycemia.
7. Assess for concomitant Axis II personality disorder indicators, with special attention to the symptomatology associated with cluster B personality disorders.
8. Assess risk as anxiety can increase the risk for suicide.

Treatment Guidelines

1. Cognitive Behavior Therapy (CBT) is an empirically supported treatment recommended by the APA (Chambless et al., 1988), which may include but is not limited to:
 - In-vivo or imaginal exposure (e.g. desensitization) (Barlow, 1996)
 - Changing internal cognitions (e.g., explore cognitive messages that trigger anxiety responses and help retrain client in adaptive responses)
 - Stress Management (e.g., assertiveness training)
2. Psychosocial Education is an important component of this treatment and may include:
 - Self help books
 - Structured homework assignments
 - Family education
 - Support groups
3. Family Therapy to enable family members to establish appropriate ways of dealing with the feared situation and assist the client in the reduction of avoidant behaviors.
4. Psychopharmacological medication is recommended if symptoms are unresponsive to psychotherapeutic interventions, or if the symptoms are incapacitating. Medications used include:

- Antidepressants – Should be maintained for at least 5 to 6 months, then tapered slowly to avoid reactivation of anxiety symptoms (March et al., 1997; American Psychiatric Association, 1998; Ballenger et al., 1998)
- Benzodiazepines – (*Contraindicated if assessment reveals significant substance abuse potential or history of substance addiction. See additional comments below.*)
- Beta-blockers
- Buspirone – approved by the FDA in the mid-1980s as an anxiolytic, buspirone has the advantage of being non-habit forming and has no abuse potential (Stahl, 1996). It is useful in the treatment of Generalized Anxiety Disorder, often as an adjunct to SSRIs (Lydiard et al., 1996).

Mood Stabilizers

For benzodiazepines, use lowest effective dose on an as-needed basis. Current standard of practice is to treat for 6-12 months before trying to taper and discontinue. Routine dosing should be reserved for intractable anxiety.

When tapering benzodiazepines, go slowly. Do not abruptly discontinue benzodiazepines or permit client to taper/discontinue them without supervision.

- Monitor for rebound symptoms – these usually abate in 2-4 weeks. If they do, continue tapering. If symptoms do not abate or if client worsens, raise dose, still trying to achieve lowest effective dose.
- Educate client and family regarding tapering method and possibility of rebound symptoms.

Bibliography

Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, Gibbons R: Time-related predictors of suicide in major affective disorder. *Am J Psychiatry* 1990; 147:1189–1194

American Psychiatric Association. (1998). Practice guidelines for the treatment of patients with panic disorder. *American Journal of Psychiatry*, 155 (Suppl. 12), 1–34.

Ballenger, J. C., Davidson, J. R., Lecrubier, Y., Nutt, D. J., Bobes, J., Beidel, D. C., Ono, Y., & Westenberg, H. G. (1998). Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. *Journal of Clinical Psychiatry*, 59(Suppl. 17), 54–60.

Barlow, D. H., & Lehman, C. L. (1996). Advances in the psychosocial treatment of anxiety disorders. Implications for national health care; *Archives of General Psychiatry* 53, 727–735.

Brunello N. et al. (2000). Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, co morbidity and treatment. *J Affect Disord* Oct;60(1):61-74

[Chambless, D. K., Baker, M. J., Baucom, D. H., Beutler, L. E., et al \(1998\). Update on empirically validated therapies II *The Clinical Psychologist* 51, 3–16.](#)

Copeland, J.N. (2001). Social phobia: etiology, neurobiology and treatment. *Clin Psychiatry* 62 Suppl 1:25-35

Dugas MJ et al (2000). Treatment of GAD. Targeting intolerance of uncertainty in two types of worry. *Behav Modif* Oct;24(5): 635-57

Enright, S. (2000). Cognitive Therapy: a practical guide. *Practitioner* May; 244(1610): 426-8; 430-1;433

Jefferson J.W. (2001). Benzodiazepines and anticonvulsants for social phobia. *J Clin Psychiatry* 62 Suppl 1:50-3

Ladouceur R et al (2000). Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. *J Consult Psychol* Dec;68(6): 957-64

Lydiard, R. B., Brawman-Mintzer, O., & Ballenger, J. C. (1996). Recent developments in the psychopharmacology of anxiety disorders; *Journal of Consulting and Clinical Psychology* 64, 660–668.

March, J. S., Frances, A., Carpenter, D., & Kahn, D. A. (1997). Treatment of obsessive-compulsive disorder. The Expert Consensus Panel for obsessive-compulsive disorder. *Journal of Clinical Psychiatry*, 58, 2–72.

NIMH (Sept 25-27, 1991). Panic disorder consensus statement.

Otto M.W. et al (2000). Empirically supported treatments for panic disorder: costs, benefits and stepped care. *J Consult Clin Psychol* Aug; 68(4):556-63

Van Dam-Baggen R et al (2000). Group skills training or cognitive group therapy as the treatment of choice for generalized social phobia?; *J Anxiety Disord* Sep-Oct;14(5) :437-51